Cayman Pharma was formed in October of 2006 by the merger of two companies with very different geographic origins. Both, however, had unparalleled experience and expertise in Prostaglandin Chemistry. One was Cayman Chemical, a research biochemical company with global recognition as an expert in the field of lipid chemistry. The other was NeraPharm, a company located within the Spolana complex north of Prague since the late 1970s, but only operating as an independent legal entity since 2002. NeraPharm was conceived during the era of Soviet economic domination and central planning. Their goal, which was largely achieved, was to implement independent production of important veterinary prostaglandins for the entire Eastern Bloc. Cayman had its beginnings just a few years later, in 1980. Cayman's vision, also largely accomplished, was to demonstrate that naturally occurring prostaglandins from corals could be an economical and versatile raw material. Targeting the research community instead of the human and veterinary market, Cayman was soon selling a wide variety of extremely pure and valuable prostaglandin standards.
Cayman Pharma represents the joining of almost 60 years of experience with prostaglandin synthesis and biochemistry. NeraPharm brings to the new company a deep understanding of GMP manufacturing under US FDA and EMEA standards, and many years of experience supplying pharmaceutical grade active ingredients. The Czech company also provides Cayman with a tremendous boost in manufacturing capacity. Cayman, on the other hand, brings cutting edge knowledge both in the research field and in GMP methods for the most advanced prostaglandin compounds. Drug candidates for newer indications such as glaucoma, male and female sexual dysfunction, and pulmonary hypertension are all part of the Cayman portfolio.
Cayman Pharma will strive to make the best possible use of its joint EU and US GMP manufacturing operations to ensure that the prostaglandin API that the customer needs is properly certified and ready for release.